Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Shares Outstanding (Weighted Average) (2019 - 2025)

Goldenwell Biotech's Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $99.0 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 2.66% year-over-year to $99.0 million; the TTM value through Sep 2025 reached $99.0 million, up 2.66%, while the annual FY2024 figure was $99.0 million, 2.66% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $99.0 million in Q3 2025 per GWLL's latest filing, up from $9.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $99.0 million in Q4 2024 to a low of $9.9 million in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $85.1 million, with a median of $96.4 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 14.15% in 2021, then crashed 89.73% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $91.3 million in 2021, then grew by 5.6% to $96.4 million in 2022, then changed by 0.0% to $96.4 million in 2023, then increased by 2.66% to $99.0 million in 2024, then changed by 0.0% to $99.0 million in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Shares Outstanding (Weighted Average) are $99.0 million (Q3 2025), $9.9 million (Q2 2025), and $9.9 million (Q1 2025).